Literature DB >> 12684409

Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.

Catherine Shannon1, Judy Kirk, Rebecca Barnetson, Justin Evans, Margaret Schnitzler, Michael Quinn, Neville Hacker, Alex Crandon, Paul Harnett.   

Abstract

PURPOSE: Families with hereditary nonpolyposis colorectal cancer (HNPCC) have an increased lifetime risk of endometrial (40%) and ovarian (10%) carcinomas. Endometrial and ovarian carcinomas from members of these families frequently display a mutator phenotype as manifest by high levels of microsatellite instability (MSI-H). Microsatellite instability (MSI) occurs in 17-32% of sporadic endometrial carcinomas and 3-17% of sporadic ovarian carcinomas. We hypothesized that there might be a higher rate of MSI in tumors from women with synchronous primary carcinomas of the ovary and endometrium. EXPERIMENTAL
DESIGN: We identified 52 cases of synchronous tumors of the ovary and endometrium from the databases of four gynecological oncology units. Archival material and clinical data were available on 45 of these patients. We examined DNA extracted from ovarian and endometrial tumor tissue for MSI using DNA extracted from normal tissue of that patient as a germ-line DNA control. MSI was assessed using a panel of five standard microsatellite markers: D2S123, D5S346, D17S250, BAT25, and BAT26. MSI-H was defined by more than two markers being positive. Low-level MSI (MSI-L) was defined as one or two markers positive and microsatellite stable (MSS) was defined as no markers positive.
RESULTS: The 45 patients had a median age at diagnosis of 53 years. Of a total of 134 samples analyzed, only three samples (3.3%) were MSI-H. No patient had high levels of MSI in both ovarian and endometrial tumors. One ovarian carcinoma had five of five markers positive with the corresponding endometrial carcinoma being MSI-L. Two endometrial carcinomas were MSI-H, and the corresponding ovarian carcinomas were MSI-L and MSS, respectively. Seven ovarian tumors and seven endometrial tumors were MSI-L. The majority of patients had early-stage ovarian carcinoma [International Federation of Gynecology and Obstetrics (FIGO) stage I, 44.4%; stage II, 26.7%; and stage III, 26.6%]. Eighty-two % of the endometrial primaries were FIGO stage I. Progression-free survival was significantly better for patients with synchronous primaries than those presenting with ovarian carcinoma alone [adjusted hazards ratio, 1.94; P = 0.023; 95% confidence interval, 1.096-3.44].
CONCLUSION: Synchronous primary carcinomas of the ovary and endometrium are unlikely to be part of the HNPCC syndrome unless the family history is in keeping with the modified Amsterdam criteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684409

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 2.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

Review 3.  Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome.

Authors:  Linnea M Baudhuin; Lawrence J Burgart; Olga Leontovich; Stephen N Thibodeau
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.

Authors:  Christine S Walsh; Audra Blum; Ann Walts; Randa Alsabeh; Hang Tran; H Phillip Koeffler; Beth Y Karlan
Journal:  Gynecol Oncol       Date:  2010-01-19       Impact factor: 5.482

5.  Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study.

Authors:  Yong Kuei Lim; Rama Padma; Lilian Foo; Yin Nin Chia; Philip Yam; John Chia; Hs Khoo-Tan; Swee Peng Yap; Richard Yeo
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

6.  Accurately estimating the length distributions of genomic micro-satellites by tumor purity deconvolution.

Authors:  Yixuan Wang; Xuanping Zhang; Xiao Xiao; Fei-Ran Zhang; Xinxing Yan; Xuan Feng; Zhongmeng Zhao; Yanfang Guan; Jiayin Wang
Journal:  BMC Bioinformatics       Date:  2020-03-11       Impact factor: 3.169

Review 7.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

Review 8.  Potential for Mitochondrial DNA Sequencing in the Differential Diagnosis of Gynaecological Malignancies.

Authors:  Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.